Trial Profile

Pivotal phase III study of T cell vaccine Tcelna in patients with relapsing-remitting multiple sclerosis.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imilecleucel-T (Primary)
Indications Multiple sclerosis
Focus Registrational; Therapeutic Use
Sponsors Acer Therapeutics; Opexa Therapeutics

Most Recent Events

19 Sep 2017 According to a Acer Therapeutics media release, Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics.
08 Nov 2011 Opexa plans to initiate a phase IIb trial in patients with secondary progressive multiple sclerosis, while remaining committed to further advancing the product in relapsing-remitting multiple sclerosis at a later date.
06 Jan 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com